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ABSTRACT
Objectives: To evaluate the association between
restless legs syndrome (RLS) and incident
cardiovascular disease (CVD).
Design: Prospective cohort study.
Setting: Women’s Health Study (WHS) and
Physicians’ Health Study (PHS), USA.
Participants: 29756 female health professionals aged
$45 years and 19182 male physicians aged
$40 years at baseline.
Main outcome measures: Main outcome was
incidence of major CVD; secondary outcomes were
ﬁrst incidence of myocardial infarction, stroke, death
due to CVD or coronary revascularisation.
Results: 3487 (11.7%) women and 1373 (7.2%) men
met International Restless Legs Study Group criteria
for RLS. In the WHS 450 major CVD events occurred
and 1064 major CVD events were conﬁrmed in the
PHS. In both cohorts, RLS was not associated with
increased risk of major CVD, stroke, myocardial
infarction, CVD death or coronary revascularisation.
After adjustment for major vascular risk factors, the
HRs (95% CI) for major CVD were 1.15 (0.88 to 1.50)
in women and 1.01 (0.81 to 1.25) in men. Highest
multivariable-adjusted HRs were 1.29 (0.91 to 1.82)
for total stroke in women and 1.22 (0.87 to 1.70) for
CVD death in men. Excluding participants with
comorbidities potentially leading to RLS did not
substantially change the effect estimates.
Conclusions: In these large prospective studies of
female and male health professionals, RLS was not
associated with an increased risk of any incident CVD
event. The data do not support the hypothesis that RLS
is a marker of increased risk of vascular disease.
INTRODUCTION
Restless legs syndrome (RLS) is a movement
disorder characterised by an urge to move
the legs, typically during rest, and is mostly
accompanied by unpleasant leg sensations.
This syndrome has been increasingly studied
over the last years. According to results from
population-based studies, RLS is a common
disease with an estimated prevalence ranging
from 4% to 29%.
1 2 The prevalence of RLS
increases with age, and women are predom-
inately affected. There is increasing evidence
that dysfunction of the dopaminergic system
is one underlying cause for the syndrome,
3
although the precise mechanisms of this
disease are still unknown. In addition, results
from genetic studies indicate a genetic
predisposition for the disorder.
45
Different comorbidities have been reported
to be associated with RLS. Particularly, the
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ARTICLE SUMMARY
Article focus
- The aim of this study is to evaluate the
association between RLS and incident cardio-
vascular events in two large prospective cohort
studies.
Key messages
- The results of our two large prospective cohorts
do not suggest that either women or men
suffering from RLS are at increased risk for
any vascular disease event.
- RLS should not be considered a marker for
increased CVD risk.
Strengths and limitations of this study
- Strengths of this study include the large number
of participants and outcome events, the prospec-
tive study design, the standardised assessment
of RLS according to the four minimal diagnostic
criteria and conﬁrmation of CVD cases by
medical record review.
- The following limitations should be considered:
the information on RLS was self-reported and
misclassiﬁcation of cases is possible. No infor-
mation on frequency, severity and duration of
RLS symptoms was available and both cohorts
consist of white health professionals, which may
limit the generalisability of the results to other
populations.
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Open Access Researchrelationship between RLS and prevalent cardiovascular
disease (CVD), as suggested by several cross-sectional
studies,
6e12 has gained attention due to the high preva-
lence of both conditions in the general population. In
addition, one prospective study from the UK has
reported an association between RLS and incident stroke,
which was not found for ischaemic heart disease.
13 As
potential mechanisms for this relationship, an unfav-
ourable CVD risk factor proﬁle and an elevated activity of
the sympathetic nervous system resulting in tachycardia
and hypertension have been proposed.
14 15 However,
data on the association between RLS and vascular risk
factors are inconsistent and studies evaluating the asso-
ciation between RLS and incident CVD are lacking.
Evaluating the association between RLS and CVD is of
substantial public health importance because of the high
prevalence of RLS. In addition, a relationship between
these two diseases would have clinical implications for
the management and treatment of patients and would
further stimulate research to identify potential common
pathophysiological mechanisms. The cross-sectional
design of previous studies, however, does not allow
determining the direction of association between RLS
and CVD and prospective data are lacking. We therefore
sought to evaluate the association between RLS and risk
of incident CVD in two large prospective cohort studies,
the Women’s Health Study (WHS) and the Physicians’
Health Study (PHS).
METHODS
Study populations
The design and methods of both cohorts have been
described in detail previously.
16e19 Brieﬂy, the WHS was
a randomised placebo-controlled trial designed to test
the risks and beneﬁts of low-dose aspirin and vitamin E in
the primary prevention of CVD and cancer among
apparently healthy women. A total of 39876 US female
healthcare professionals aged 45 years or older at study
entry (1992e1995) without a history of CVD, cancer or
other major illnesses were randomly assigned to receive
active aspirin (100 mg on alternate days), active vitamin E
(600 IU on alternate days), both active agents or both
placebos. Baseline information was self-reported and
collected by a mailed questionnaire that asked about
many cardiovascular risk factors and lifestyle variables.
Twice in the ﬁrst year and yearly thereafter, participants
were sent follow-up questionnaires asking about study
outcomes and other information during the study
period. After the termination of the trial in March 2004,
the women who were still alive and willing to participate
entered an observational follow-up. The return date of
the 108-month questionnaire containing questions on
RLS was deﬁned as new baseline for this analysis. Of the
33092 women in active follow-up at 108 months, we
excluded 1722 women with missing RLS information,
1614 women who reported CVD events (myocardial
infarction, stroke, CVD death, coronary revascularisa-
tion) and angina prior to receiving the 108-months
questionnaire, leaving a total of 29756 women free of
CVD or angina for this analysis.
The Physicians’ Health Study I (PHS I) was a rando-
mised, double-blind placebo-controlled trial to test the
beneﬁts and risks of low-dose aspirin (325 mg) and
b-carotene (50 mg) in the primary prevention of CVD
and cancer among 22071 apparently healthy physicians
aged 40e84 years at baseline in 1982. Baseline informa-
tion was self-reported and collected by means of a mailed
questionnaire that asked about many cardiovascular risk
factors and lifestyle variables. Every 6 months in the ﬁrst
year and yearly thereafter, follow-up questionnaires were
sent to the participants. Since the trials’ termination in
1995, the men are continued to be followed either on an
observational basis or as part of the Physician’s Health
Study II (PHS II).
The PHS II was launched in 1997. The PHS II is an
ongoing randomised, double-blind placebo-controlled
trial to test the effects of vitamin C (500 mg), vitamin E
(400 IU), b-carotene (50 mg) and a daily multivitamin
(Centrum Silver) in the prevention of total and prostate
cancer, CVD and age-related eye disease among 14641
US male physicians aged 55 years and older, including
a total of 7,641 PHS I participants who were willing and
eligible to enter the PHS II. Baseline information was self-
reported, and follow-up information was collected annu-
ally by mailed questionnaires. For the purpose of this
analysis, we pooled data from the PHS I and PHS II,
yielding a total of 29071 participants. The return date of
the questionnaire containing the RLS question (216-
month questionnaire for PHS I participants and 12-
month questionnaire for PHS II participants) was deﬁned
as new baseline for this analysis. At this time point, 24505
men were still in active follow-up. We excluded 1579 men
with missing RLS questionnaire information and 3744
men with CVD events and angina prior to the RLS
assessment, leaving a total of 19182 men free of angina
and CVD at our deﬁned baseline for our analysis.
All participants of the WHS and the PHS provided
written informed consent, and the institutional review
board of Brigham and Women’s Hospital, Boston, MA,
approved the studies as well as the analyses presented
here.
Assessment of RLS
RLS is diagnosed by presence of speciﬁc symptoms, and
the diagnostic criteria have been established by the
International Restless Legs Study Group (IRLSSG). We
have implemented standardised questions in both
cohorts addressing the four minimal diagnostic criteria
of the IRLSSG. Participants were asked: “Do you have
unpleasant leg sensations (like crawling, paraesthesias or
pain) combined with a motor restlessness and an urge to
move?”, “Do these symptoms occur only at rest and does
moving improve them?”, “Are these symptoms worse in
the evening or at night compared with the morning?”
Participants who answered yes to all the three questions
were deﬁned as having RLS. This questionnaire has been
established
20e22 and validated
23 in previous studies from
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diagnosis of RLS with a physician’s diagnosis as a gold
standard showed good agreement (unweighted k¼0.67,
p<0.001).
23
Outcome ascertainment
Participants of both cohorts were asked to report the
occurrence of cardiovascular events including myocar-
dial infarction and stroke during follow-up. In addition,
information on coronary revascularisation procedures
(bypass surgery and percutaneous coronary angioplasty)
was collected. Medical records were obtained for all
cardiovascular events including coronary revascularisa-
tion in the WHS and for all cardiovascular events, but
not for coronary revascularisation, in the PHS and were
reviewed by an end points committee of physicians. The
occurrence of myocardial infarction was conﬁrmed if
symptoms met WHO criteria and if the event was asso-
ciated with abnormal levels of cardiac enzymes or diag-
nostic ECG. Non-fatal stroke was conﬁrmed if the
participant had a new focal neurological deﬁcit of
sudden onset and vascular origin that persisted for more
than 24 h. Stroke was classiﬁed into its major subtypes
based on available clinical and diagnostic test informa-
tion, including brain scans with excellent inter-rater
agreement.
24 25 Cardiovascular deaths were conﬁrmed
by reviews of autopsy reports, death certiﬁcates, medical
records and information obtained from next of kin or
other family members. Major CVD was deﬁned as
a combined end point of non-fatal stroke, non-fatal
myocardial infarction or death from CVD events.
Statistical analysis
We analysed the association between RLS and incident
CVD separately in both studies. Baseline characteristics
were compared with respect to RLS status using the t-test
for continuous and the c
2 test for categorical variables.
Person-time was calculated from the return date of the
questionnaire containing the RLS questions (baseline
for this study) to the date of ﬁrst incident CVD event,
non-CVD death, last documented contact or end of the
study, whatever occurred ﬁrst. Information on cardio-
vascular risk factors and other covariates was updated
from the start of the cohorts until the assessment of RLS.
Cox proportional hazards models were used to eval-
uate the association between RLS and the various CVD
events. We calculated age- and multivariable-adjusted
HRs and their corresponding 95% CIs. The multivari-
able-adjusted models accounted for age, randomised
aspirin assignments, history of hypertension (yes/no)
history of diabetes (yes/no), history of cholesterol level
$240 mg/dl (yes/no), parental history of myocardial
infarction before the age of 60 years (yes/no), alcohol
consumption (rarely/never, 1e3/month, 1e6/week,
$1/day), smoking status (never, past, current), body
mass index (BMI) (<25, 25e29.9, $30 kg/m
2), exer-
cise (WHS: rarely/never, <1/week, 1e3/week, $4/
w e e k ;P H S :r a r e l y / n e v e r ,#1/week, 2e4/week, 5e7/
week), history of migraine (yes/no) and post-
menopausal hormone use (WHS: never, past, current).
Additional adjustment for race, geographic location,
depression, iron supplementation use, Parkinson’s
disease, snoring (PHS only), sleep duration (PHS only),
fatigue (WHS only), number of pregnancies (WHS
only), age at menarche (WHS only), postmenopausal
status (WHS only), oral contraceptive use (WHS only)
and analgesic use including aspirin, non-steroidal anti-
inﬂammatory drugs, acetaminophen (WHS only) and
aspirin containing drugs (WHS only) did not change
t h ee f f e c te s t i m a t eo fR L So na n yC V De v e n tb ym o r e
than 10%.
A missing value indicator was incorporated in the
outcome models for covariates if the number of partici-
pants with missing information was $100. We assigned
participants with missing values to the covariate refer-
ence category if the number of missing information was
<100. No covariate in the primary analysis had more
than 4% missing.
We evaluated effect modiﬁcation by age (<60, 60e<70,
70e<80, $80 years), iron supplementation use (yes/no),
BMI (<25 kg/m
2,2 5 e29.9 kg/m
2, $30 kg/m
2), smoking
status (never, past, current), history of hypertension
(yes/no), fatigue (WHS only) and number of pregnan-
cies (WHS only). Effect modiﬁcation was tested by
including an interaction term for RLS and the potential
effect modiﬁer to the outcome model.
The proportional hazards assumption was tested by
including an interaction term for RLS status and loga-
rithm of follow-up time for major CVD in age-adjusted
models. We found no statistically signiﬁcant violation.
We performed a sensitivity analysis by excluding
participants with a history of polyneuropathy, kidney
disease, liver disease, liver cirrhosis (PHS only), rheu-
matoid arthritis, intermittent claudication and partici-
pants who underwent peripheral artery disease surgery.
The information on these covariates was updated from
the start of the cohorts until assessment of the ques-
tionnaire addressing RLS.
For all analyses, we used SAS (V.9.1.3, SAS Institute
Inc.). All p values were two tailed, and p<0.05 was
considered statistically signiﬁcant.
RESULTS
Baseline characteristics
The baseline characteristics of participants according to
RLS status are presented in table 1 for the WHS and in
table 2 for the PHS. The prevalence for RLS was 11.7%
among women and 7.2% among men. In contrast to the
WHS, we observed an age difference according to RLS
status in the PHS. Men with RLS had a mean age of
67.8 years and were older than men without RLS.
Compared with participants without RLS, both male and
female RLS sufferers were more likely to report a history
of hypertension, a history of diabetes and a history of
hypercholesterolaemia. With regard to lifestyle factors,
participants with RLS were more likely to have a BMI
$30 kg/m
2, to rarely/never drink and to rarely/never
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female RLS sufferers more frequently reported a history
of depression and migraine.
Risk of CVD
Women’s Health Study
A total of 450 ﬁrst major CVD events, 176 myocardial
infarctions, 245 strokes, 66 CVD deaths and 461 coro-
nary revascularisations were conﬁrmed during a mean
follow-up of 6.0 years. Age- and multivariable-adjusted
HRs (95% CI) for the association between RLS and the
various vascular events are presented in table 3. Women
with RLS had an increased age-adjusted HR of 1.42 (1.10
to 1.82) for coronary revascularisation. The association
was diminished and became insigniﬁcant after adjust-
ment for vascular risk factors. RLS was not associated
with a signiﬁcantly increased risk for major CVD,
myocardial infarction, stroke or CVD death.
Table 1 Baseline characteristics according to RLS status in the WHS (n¼29756)
No RLS (n[26269) RLS (n[3487) p Value
Demographic information
Mean age, years (SD) 63.4 (6.9) 63.3 (6.8) 0.30
Ethnicity, n (%)
White 24786 (95.1) 3376 (97.4) <0.01
Geographic location, n (%) <0.01
Northeast 5168 (19.7) 605 (17.4)
Southeast 5985 (22.8) 825 (23.7)
Midwest 9362 (35.7) 1312 (37.7)
West 5713 (21.8) 742 (21.3)
CVD risk factors, n (%)
History of hypertension 12273 (46.7) 1759 (50.4) <0.01
History of diabetes 1709 (6.5) 295 (8.5) <0.01
History of cholesterol $240 mg/dl 13850 (52.8) 2013 (57.8) <0.01
BMI categories (kg/m
2) <0.01
<25 10813 (41.8) 1302 (37.8)
25e29.9 8866 (34.3) 1195 (34.7)
$30 6177 (23.9) 950 (27.6)
Smoking status <0.01
Never 13484 (52.0) 1619 (47.0)
Past 10352 (39.9) 1504 (43.7)
Current 2083 (8.0) 321 (9.3)
Alcohol consumption 0.05
Rarely/never 11071 (42.4) 1558 (44.9)
1e3 drinks per month 3044 (11.7) 394 (11.3)
1e6 drinks per week 8969 (34.4) 1138 (32.8)
$1 drink/day 2936 (11.2) 314 (9.0)
Exercise <0.01
Rarely/never 9875 (37.6) 1380 (39.6)
<1/week 5224 (19.9) 728 (20.9)
1e3 times/week 8225 (31.3) 1064 (30.5)
$4 times/week 2939 (11.2) 314 (9.0)
Parental history of myocardial infarction 4391 (16.8) 646 (18.6) <0.01
Postmenopausal status 0.13
Premenopausal 467 (1.8) 54 (1.6)
Postmenopausal 23368 (90.8) 3082 (90.1)
Biological uncertain 1651 (6.4) 253 (7.4)
Unclear/subject unsure 264 (1.0) 33 (0.96)
Postmenopausal hormone use <0.01
Never 5626 (22.3) 636 (18.9)
Past 6347 (25.2) 836 (24.9)
Current 13225 (52.5) 1891 (56.2)
Other covariates, n (%)
History of migraine 5509 (21.0) 909 (26.1) <0.01
History of depression 3132 (11.9) 707 (20.3) <0.01
History of Parkinson’s disease 105 (0.4) 21 (0.6) 0.08
Iron supplementation use 1028 (4.0) 124 (3.6) 0.30
Being fatigued 9101 (34.8) 1776 (51.1) <0.01
Percentages may not add up to 100% due to rounding or missing values.
BMI, body mass index; CVD, cardiovascular disease; RLS, restless legs syndrome; WHS, Women’s Health Study.
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In table 4, age- and multivariable-adjusted HRs (95% CI)
for the association between RLS and vascular outcomes in
the PHS are summarised. During a mean follow-up of
7.3 years, 1064 major CVD events, 431 myocardial infarc-
tions, 381 strokes and 389 CVD deaths were conﬁrmed. In
addition, 1352 coronary revascularisations were reported.
RLS at baseline was not associated with incident vascular
events in age-adjusted or multivariable-adjusted models.
Sensitivity analyses
After excluding participants with comorbid conditions
that have been associated with RLS, the lack of associa-
tion between RLS and our outcome events remained
robust, with the exception of stroke in the WHS. The
multivariable-adjusted HR increased from 1.29 (0.91 to
1.82) to 1.42 (0.99 to 2.05).
In both cohorts, the effect estimates did not change by
more than 5% when excluding a history of diabetes from
the list of confounding factors in multivariable-adjusted
models.
Effect modiﬁcation
The associations between RLS and major CVD were not
signiﬁcantly modiﬁed by age (p for interaction in the
WHS: 0.12, p for interaction in the PHS: 0.51), BMI (p
Table 2 Baseline characteristics according to RLS status in the PHS (n¼19182)
No RLS (n[17809) RLS (n[1373) p Value
Demographic information
Mean age, years (SD) 66.6 (8.7) 67.8 (8.9) <0.01
Ethnicity, n (%)
White 16091 (90.8) 1288 (94.2) <0.01
Geographic location, n (%) 0.16
Northeast 3983 (22.4) 299 (21.8)
Southeast 5137 (28.8) 359 (26.2)
Midwest 4547 (25.5) 375 (27.3)
West 4031 (22.6) 329 (24.0)
Other 111 (0.6) 11 (0.8)
CVD risk factors, n (%)
History of hypertension 8596 (48.3) 703 (51.2) 0.04
History of diabetes 1200 (6.7) 138 (10.1) <0.01
History of cholesterol $240 mg/dl 8387 (47.1) 686 (50.0) 0.04
BMI categories (kg/m
2) <0.01
<25 7550 (42.5) 519 (37.8)
25e29.9 8197 (46.1) 665 (48.5)
$30 2038 (11.5) 189 (13.8)
Smoking status 0.17
Never 9763 (54.9) 719 (52.4)
Past 7543 (42.4) 617 (45.0)
Current 495 (2.8) 37 (2.7)
Alcohol consumption <0.01
Rarely/never 3120 (17.5) 292 (21.3)
1e3 times/month 2171 (12.2) 157 (11.4)
1e6 times/week 6631 (37.3) 514 (37.4)
$1 times/day 5862 (33.0) 410 (29.9)
Exercise <0.01
Rarely/never 6174 (34.8) 536 (39.2)
#1/week 455 (2.6) 39 (2.9)
2e4 times/week 7917 (44.6) 594 (43.4)
5e7 times/week 3204 (18.1) 200 (14.6)
Parental history of myocardial infarction 1910 (10.7) 137 (10.0) 0.39
Other covariates, n (%)
History of migraine 2157 (12.1) 202 (14.7) <0.01
History of depression 1709 (9.8) 219 (16.1) <0.01
History of Parkinson’s disease 207 (1.2) 20 (1.5) 0.33
Iron supplementation use 298 (1.9) 25 (2.1) 0.73
Sleep duration $8 h 5254 (32.7) 431 (34.9) 0.11
Snoring 0.24
Never 4382 (26.9) 338 (27.0)
A few nights 6604 (40.6) 482 (38.5)
Most nights 5283 (32.5) 433 (34.6)
Percentages may not add up to 100% due to rounding or missing values.
BMI, body mass index; CVD, cardiovascular disease; PHS, Physician’s Health Study; RLS, restless legs syndrome.
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PHS: 0.28), smoking status (p for interaction in the
WHS: 0.71, p for interaction in the PHS: 0.43), iron
supplementation use (p for interaction in the WHS:
0.75, p for interaction in the PHS: 0.35), history of
hypertension (p for interaction in the WHS: 0.76, p for
interaction in the PHS: 0.43), fatigue (p for interaction
WHS: 0.91) or number of pregnancies (p for interaction
WHS: 0.92).
DISCUSSION
In this study, evaluating data from two large prospective
cohort studies of women and men, RLS was not associ-
ated with an increased risk for incident vascular events
Table 3 Age- and multivariable-adjusted HRs for incident vascular events according to RLS status in the WHS
Primary analysis (n[29756) Sensitivity analysis* (n[27649)
No RLS
history
(n[26269)
Any history of RLS
(n[3487)
No RLS
history
(n[24472)
Any history of RLS
(n[3177)
HR (95% CI) HR (95% CI)
Major cardiovascular event n¼386 n¼64 n¼338 n¼56
Age adjusted 1.00 1.25 (0.96 to 1.63) 1.00 1.27 (0.96 to 1.69)
Multivariable adjustedy 1.00 1.15 (0.88 to 1.50) 1.00 1.18 (0.89 to 1.57)
Any stroke n¼207 n¼38 n¼178 n¼35
Age adjusted 1.00 1.39 (0.98 to 1.96) 1.00 1.51 (1.05 to 2.16)
Multivariable adjustedy 1.00 1.29 (0.91 to 1.82) 1.00 1.42 (0.99 to 2.05)
Myocardial infarction n¼153 n¼23 n¼138 n¼20
Age adjusted 1.00 1.13 (0.73 to 1.75) 1.00 1.11 (0.69 to 1.77)
Multivariable adjustedy 1.00 1.01 (0.65 to 1.57) 1.00 1.00 (0.62 to 1.59)
Coronary revascularisation n¼388 n¼73 n¼346 n¼59
Age adjusted 1.00 1.42 (1.10 to 1.82) 1.00 1.30 (0.99 to 1.72)
Multivariable adjustedy 1.00 1.24 (0.96 to 1.59) 1.00 1.14 (0.86 to 1.50)
CVD death n¼57 n¼9n ¼52 n¼6
Age adjusted 1.00 1.21 (0.60 to 2.45) 1.00 0.90 (0.39 to 2.09)
Multivariable adjustedy 1.00 1.11 (0.55 to 2.25) 1.00 0.85 (0.36 to 1.98)
*2107 women with polyneuropathy, liver disease, kidney disease/failure, peripheral artery disease surgery, intermittent claudication and
rheumatoid arthritis were excluded from the analysis.
yAdjusted for age, randomised treatment assignments, history of hypertension, history of diabetes, history of hypercholesterolaemia, parental
history of myocardial infarction, history of migraine, alcohol consumption, body mass index, smoking, exercise and postmenopausal hormone
use.
CVD, cardiovascular disease; RLS, restless legs syndrome; WHS, Women’s Health Study.
Table 4 Age- and multivariable-adjusted HRs for incident vascular events according to RLS status in the PHS
Primary analysis (n[19182) Sensitivity analysis* (n[15625)
No RLS
history
(n[17809)
Any history of RLS
(n[1373)
No RLS
history
(n[14578)
Any history of RLS
(n[1047)
HR (95% CI) HR (95% CI)
Major cardiovascular event n¼974 n¼90 n¼755 n¼61
Age adjusted 1.00 1.09 (0.88 to 1.35) 1.00 1.03 (0.79 to 1.33)
Multivariable adjustedy 1.00 1.01 (0.81 to 1.25) 1.00 0.96 (0.74 to 1.25)
Any stroke n¼357 n¼24 n¼271 n¼18
Age adjusted 1.00 0.77 (0.51 to 1.17) 1.00 0.82 (0.51 to 1.33)
Multivariable adjustedy 1.00 0.73 (0.48 to 1.11) 1.00 0.79 (0.49 to 1.28)
Myocardial infarction n¼392 n¼39 n¼315 n¼25
Age adjusted 1.00 1.23 (0.88 to 1.71) 1.00 1.06 (0.70 to 1.59)
Multivariable adjustedy 1.00 1.12 (0.80 to 1.55) 1.00 0.97 (0.64 to 1.45)
Coronary revascularisation n¼1239 n¼113 n¼976 n¼87
Age adjusted 1.00 1.15 (0.95 to 1.40) 1.00 1.22 (0.98 to 1.52)
Multivariable adjustedy 1.00 1.06 (0.88 to 1.29) 1.00 1.12 (0.90 to 1.40)
CVD death n¼350 n¼39 n¼260 n¼25
Age adjusted 1.00 1.27 (0.91 to 1.77) 1.00 1.17 (0.78 to 1.77)
Multivariable adjustedy 1.00 1.22 (0.87 to 1.70) 1.00 1.13 (0.75 to 1.70)
*3557 men with a history of polyneuropathy, kidney disease, liver disease, liver cirrhosis, rheumatoid arthritis, intermittent claudication and men
who underwent peripheral artery disease surgery were excluded.
yAdjusted for age, randomised treatment assignments, history of hypertension, history of diabetes, history of hypercholesterolaemia, parental
history of myocardial infarction, history of migraine, alcohol consumption, body mass index, smoking and exercise.
CVD, cardiovascular disease; PHS, Physician’s Health Study; RLS, restless legs syndrome.
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coronary revascularisation and CVD death. Excluding
participants with comorbidities that have been associ-
ated with RLS did not substantially change our results.
Comparison with other studies
In contrast to our results, ﬁndings from several cross-
sectional studies have suggested a relationship between
RLS and prevalent CVD.
6e12 Among the 3422 partici-
pants of the Sleep Heart Health Study, those with RLS
had multivariable-adjusted OR (95% CIs) of 2.05 (1.38
to 3.04) for CVD and 2.07 (1.43 to 3.00) for coronary
artery disease. Winkelman et al
12 additionally report an
association between severity and frequency of RLS and
CVD. Compared with those without RLS, participants
who reported a RLS frequency of 16e23/month had an
OR of 3.53 (1.85 to 6.76) for CVD. Duration of disease
was not related to CVD. In our cohorts, data on
frequency and severity of symptoms were not available
and we had no information about the duration of
disease.
Two studies from Sweden, one analysing a random
sample of the female population of central Sweden aged
18e64 years and the other one evaluating a comparable
random sample of men with the same age range, report
an association between RLS and self-reported heart
disease.
9 10 As in our study, RLS was deﬁned according to
IRLSSG diagnostic criteria in these studies and the
observed overall prevalences were comparable to those
in our cohorts. The multivariable-adjusted OR for heart
disease was 2.13 (1.18 to 3.86) in the female Swedish
cohort and 2.5 (1.4 to 4.3) in the study evaluating the
random sample of Swedish men.
In the Caerphilly cohort of 1986 men, RLS was asso-
ciated with incident stroke (multivariable-adjusted OR of
1.67 (1.07 to 2.06)). In addition, the authors report an
increased but not signiﬁcant OR of 1.24 (0.89 to 1.74)
for incident ischaemic heart disease events. While we do
not ﬁnd an association between RLS and stroke in out
main analysis, the sensitivity analysis suggests potential
increased risk for stroke (RR 1.42 (0.99 to 2.05)). RLS
was not deﬁned according to IRLSSG diagnostic criteria
and the associations were not adjusted for important
vascular risk factors including hypertension and dia-
betes, which are potential limitations of this study.
13
One cross-sectional study using data from the Burden
of Obstructive Lung Disease Initiative in Iceland and
Sweden is in line with our ﬁnding.
26 A random sample of
adults aged 40 years and older was drawn from the
national registries in both countries. Benediktsdottir et al
found a signiﬁcant higher prevalence of RLS in
Icelandic women compared with those from Sweden. In
multivariable-adjusted models, RLS, deﬁned according
to IRLSSG criteria, was not associated with CVD, assessed
by a structured interview, in this study.
A high percentage of RLS patients report periodic
limb movements during sleep (PLMS), and PLMS are
considered as supportive clinical feature of RLS.
27 The
association between periodic limb movements and inci-
dent CVD has been recently evaluated among 2911 men
aged $65 years who participated in the Outcomes of
Sleep Disorders in Older Men Sleep Study.
28 Periodic
limb movements were assessed by two indices, the peri-
odic limb movement index and the periodic limb
movement arousal index. After 4.4 years of mean follow-
up, men with a periodic limb movement arousal index
$5 had a multivariable-adjusted HR of 1.26 (1.01 to
1.56) for all-cause CVD compared with those with the
lowest index category. The periodic limb movement
index was not statistically signiﬁcant associated with all-
cause CVD (HR 1.25, 95% CI 1.00 to 1.56), which was
deﬁned as a composite end point of coronary heart
disease, cerebrovascular disease and peripheral artery
disease. When evaluating the different end points sepa-
rately, incident peripheral artery disease was the only
CVD event that was signiﬁcantly associated with one of
the indices in multivariable-adjusted models (HR 2.00,
95% CI 1.14 to 3.49). Although PLMS is frequently
reported by RLS sufferers, it is not exclusively related to
RLS and occurs in other sleep-related disorders and
medical conditions. Since the frequency of RLS sufferers
could not be determined in the previous mentioned
study, the results cannot be translated to a RLS popula-
tion and the comparability of these results to our study is
limited.
RLS can be distinguished in idiopathic and secondary
forms. A variety of disorders have been identiﬁed to be
associated with secondary RLS including anaemia, iron
deﬁciency, rheumatoid arthritis, polyneuropathies and
reduced renal function. La Manna et al evaluated the
association between RLS and incident CVD events
among 100 end-stage kidney disease patients who were
on dialysis three times a week.
29 After 18 months of
follow-up, patients with secondary RLS had an increased
risk for CVD events (myocardial infarction, stroke or
peripheral artery occlusion), which, however, did not
reach statistical signiﬁcance. In addition, patients with
RLS had higher ﬁbrinogen levels, albumin levels, white
blood cell counts and higher overall mortality,
suggesting that RLS status could be an indicator for
poorer health status. Since the study analysed a very
distinct population, the comparability of these results
with studies in healthier populations including ours is
limited.
A possible explanation for the discrepancy between
our results and those of previous studies is the
prospective cohort design, which allows the assessment
of incident CVD cases. Thus, while RLS does not seem to
be a risk factor for subsequent CVD, it might be an
indicator of a poor health status due to the presence of
several, especially cardiovascular, comorbidities.
Strengths and limitations
Our study has several strengths including the large
number of participants in both cohorts, large number of
outcome events, prospective design and standardised
assessment of RLS according to the four minimal diag-
nostic criteria of the IRLSSG. Furthermore, incident
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addition, information on many comorbidities and life-
style factors was available allowing us to adjust for
potential confounders.
The following limitations should be considered when
interpreting our results. First, information on RLS was
self-reported and potential misclassiﬁcation is possible.
However, the questionnaire has been successfully used
and validated in previous cohorts from Germany and
Italy, and the prevalences of RLS in both cohorts are
similar to those reported in other population-based
studies.
1 Furthermore, both cohorts consist of health
professionals and previous studies indicate that partici-
pants with a health profession accurately report infor-
mation.
30 Moreover, we have excluded participants with
comorbidities potentially mimicking RLS syndromes in
sensitivity analysis and the results were largely
unchanged. Second, we had no information on
frequency, severity and duration of RLS symptoms.
Third, residual and unmeasurable confounding remains
possible as our study is observational. However, we are
not aware of any factor that, if controlled for, would
establish an association between RLS and CVD. Fourth,
both of our cohorts consist of predominately white
health professionals, which may limit generalisability to
other populations. However, we have no reason to
believe that potential biological associations between
RLS and CVD are different in our compared with other
populations.
Clinical implications
Results of these two large prospective studies do not
suggest that RLS is a marker for increased risk of CVD
independent of other cardiovascular risk factors.
However, our data also indicate that the prevalence of
RLS increases with several comorbidities including
traditional CVD risk factors like BMI, hypertension and
diabetes. Therefore, patients diagnosed with RLS should
be carefully screened for relevant comorbidities and
subsequently treated.
Unanswered questions and future research
RLS is a complex disease and the mechanisms under-
lying the disease have not been fully understood yet.
Understanding the role of diverse comorbidities for the
onset of RLS would be an important research target for
the future in order to establish strategies to prevent the
disease.
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